US20030138966A1 - Process for separating and analyzing hydrophobic proteins using thin layer chromatography - Google Patents
Process for separating and analyzing hydrophobic proteins using thin layer chromatography Download PDFInfo
- Publication number
- US20030138966A1 US20030138966A1 US09/190,455 US19045598A US2003138966A1 US 20030138966 A1 US20030138966 A1 US 20030138966A1 US 19045598 A US19045598 A US 19045598A US 2003138966 A1 US2003138966 A1 US 2003138966A1
- Authority
- US
- United States
- Prior art keywords
- hydrophobic
- protein
- proteins
- hcp
- layer chromatography
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 55
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 55
- 230000002209 hydrophobic effect Effects 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims abstract description 36
- 238000004809 thin layer chromatography Methods 0.000 title claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 11
- 239000012634 fragment Substances 0.000 claims abstract description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- 230000001900 immune effect Effects 0.000 claims description 11
- 230000004048 modification Effects 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims 1
- 238000007447 staining method Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 7
- 238000002965 ELISA Methods 0.000 abstract description 4
- 239000003125 aqueous solvent Substances 0.000 abstract description 4
- 238000004587 chromatography analysis Methods 0.000 abstract description 4
- 238000007796 conventional method Methods 0.000 abstract description 2
- 102000035118 modified proteins Human genes 0.000 abstract description 2
- 108091005573 modified proteins Proteins 0.000 abstract description 2
- 238000001514 detection method Methods 0.000 description 20
- 238000011002 quantification Methods 0.000 description 10
- 102100040971 Pulmonary surfactant-associated protein C Human genes 0.000 description 7
- 239000012535 impurity Substances 0.000 description 6
- 108010007125 Pulmonary Surfactant-Associated Protein C Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101000612671 Homo sapiens Pulmonary surfactant-associated protein C Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000013375 chromatographic separation Methods 0.000 description 3
- 150000002009 diols Chemical class 0.000 description 3
- 238000001378 electrochemiluminescence detection Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000009145 protein modification Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000013315 hypercross-linked polymer Substances 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000011138 biotechnological process Methods 0.000 description 1
- 238000013452 biotechnological production Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000004492 methyl ester group Chemical group 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
Definitions
- the invention relates to a process for the detection, identification and quantification of hydrophobic proteins, protein fragments and modifications, and of hydrophobic peptides.
- the analytes to be quantified are usually present only in traces. Often, straight hydrophobic proteins are additionally associated with other lipophilic substances (e.g., lipids), which makes quantification according to conventional methods impossible. In ELISA, the components are not separated from one another.
- the aim of the invention is to provide a process which allows even strongly hydrophobic proteins, protein fragments and modifications and also strongly hydrophobic peptides to be separated, identified and quantified.
- a further aim is to make available a process which makes possible the determination and quantification of, for example, proteins which are slightly modified by acetylation or oxidation.
- HCP hydrophobic host-cell protein impurities
- the object of the invention is therefore a process for the separation, identification and quantification of strongly hydrophobic proteins, protein fragments and modifications and also of strongly hydrophobic peptides, which comprises dissolving the samples to be investigated in an organic medium, subjecting them to thin-layer chromatography and rendering the hydrophobic proteins visible immunologically.
- chromatography plates include all plates having a coating suitable for separation of hydrophobic mixtures in organic media.
- HPTLC plates those which have chemically-modified silicon layers, such as HPTLC plates named Diol, CN, NH2, RP-2, RP-8 and RP-18.
- HPTLC plates those which prove particularly suitable are the HPTLC plates marketed by Merck Darmstadt under the trade name Diol, which have a modified silica matrix.
- suitable mobile phases for thin-layer chromatography are organic solvents and solvent mixtures, e.g., of chloroform and methanol.
- Mixtures of nonpolar and polar solvents are particularly expedient, possible nonpolar solvents, in particular, being chloroform, methylene chloride and toluene, and polar solvents being short-chain alcohols, particularly methanol, ethanol and isopropanol.
- Hydrophobic proteins, protein fragments and modifications and hydrophobic peptides refers to proteins, protein fragments and protein modifications and peptides which, without the aid of a detergent, are poorly soluble in aqueous solvent systems, such as membrane proteins.
- Surfactant protein C is such a hydrophobic protein.
- strongly hydrophobic is meant proteins, protein fragments and protein modifications or peptides which are essentially insoluble in an aqueous solvent system.
- Protein fragment refers to a protein which forms part of a complete sequence of a naturally occurring or artificial (synthetic) protein.
- Protein modification refers to a protein which differs by addition, substitution or deletion of one or more amino acids or chemical modifications, like alkylation, acylation, esterification and oxidation (for example, oxidation of thio radicals) of amino acids, as compared to the naturally occurring or artificial protein.
- r-SP-C disclosed in WO 95/32992 (copending U.S. application Ser. No. 08/750,194) is a modification of natural (human) SP-C.
- the detection step in the process can be carried out in different ways.
- an immunological detection method it is carried out with the help of an antibody which (preferably specifically) binds the hydrophobic protein (HP) to be detected.
- TLC thin layer chromatography
- This antibody can carry a label, and this label then provides the basis for detection.
- a second antibody carrying a label
- Such methods for immunological detection of proteins using antibodies are well known in the art and are, for example, applied in ELISA tests and Western blotting analyses.
- the kind of (primary) antibody depends on the kind of hydrophobic protein to be detected.
- the second antibody will be an anti-“primary antibody”-antibody.
- the detection of the hydrophobic protein on a plate is also achieved by way of conventional staining with a suitable reagent.
- Reagents used for staining of proteins are well known in the art and include, e.g., Coomassie, Ponceau S and silver.
- the plates are dried after thin-layer chromatographic separation.
- the plates are incubated with a suitable blocking solution, e.g. gelatin or protein.
- the plates are then incubated with the primary antibody. If this does not carry a label, detection can be carried out with the aid of a labeled second antibody.
- detection all commercially available detection processes can be used. After removal of excess first antibody by washing, incubation is carried out with a labeled second antibody. After washing, the labeled antibodies are detected.
- r-SP-C refers to recombinant surfactant protein C or modified derivatives of r-SP-C.
- the process is advantageously applied in the detection of hydrophobic impurities (hydrophobic host cell proteins) which are encountered in the production of r-SP-C with the host cells, such as E. coli .
- hydrophobic impurities hydrophobic host cell proteins
- Such process for production of r-SP-C is, for example, disclosed in WO 95/32992 (copending application Ser. No. 08/750,194, pages 10 to 12), which shows how to obtain the starting material for the following example.
- the example (step 1) describes the is preparation of antigens (HCP antigens) which are used for the generation of the antibodies (primary antibody) against HCP impurities (step 2).
- HCP antigens antigens
- Such antibodies are required in the immunological detection step of the subject process when it is desired to detect HCP impurities.
- HCPs are withdrawn from a fermentation phase in which the r-SP-C is pure to 80 to 90%.
- 60 g of inclusion bodies isolated by filtration and/or centrifugation from a 10 1 blank fermentation are used after lyophilization for about 96 hours.
- the individual sera at various dilutions are analyzed by means of a new method described as immuno-thin-layer chromatography (immuno-TLC). Dilutions of 1:5000, 1:1000, 1:20,000 and 1:50,000 are used in order to analyze 4, 15, 62.5 and 250 ng of HCP. At a dilution of 1:10,000 all rabbit antibodies investigated recognize HCP components in proportion to the amount of total protein. Antisera having a similar titer are pooled and reanalyzed. The serum is characterized according to standard procedures and stored in aliquots at ⁇ 20° C. (The term “immuno-TLC” refers to the subject process when an immunological method is used in the detection step.)
- the samples to be analyzed are dried in a vacuum concentrator and dissolved in 20 to 200 ⁇ l of CHCl 3 /MeOH.
- HPTLC plates having a modified silica matrix such as are marketed by Merck Darmstadt under the trade name Diol, are used.
- the application of the samples to the HPTLC plates is carried out automatically using a Lingomat IV (Camag, Berlin).
- the plates are dried.
- the dried HPTLC plates are incubated for 4 hours with 3% strength fish gelatin in PBS which contains 150 mM NaCl, 12 mM Na 2 HPO 4 and 3 mM NaH 2 PO 4 (pH 7,4). The plates are then incubated overnight and lightly shaken in the presence of the primary antibody, usually at a dilution of 1:10,000. Unbound antibodies are removed by washing several times with Tris Buffer Saline/Tween (TBS/T) from 4 mM tris HCl, 100 mM NaCl, 0.05% Tween 20 (pH 7.4).
- TBS/T Tris Buffer Saline/Tween
- the plates are incubated for 2 hours with horseradish peroxidase-conjugated secondary antibody at a dilution of 1:80,000 in the TBS/T. Unbound antibodies are removed, as described above, by washing the plates several times with TBS/T. Immunoreactive complexes are visualized using an ECL detection system from Amersham Buchler. The plates are incubated for 20 to 50 seconds with an X-ray film (Hyperfilm Amersham).
- the X-ray films are digitalized using a video-imager (Cybertech, Berlin, Germany).
- the signal intensities on the X-ray films are analyzed by computer analysis using Wincam software (Cybertech).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
- This application is a continuation-in-part of International Application No. PCT/EP97/02463, filed May 14, 1998.
- The invention relates to a process for the detection, identification and quantification of hydrophobic proteins, protein fragments and modifications, and of hydrophobic peptides.
- The quantification of hydrophobic proteins is not possible or is only inadequately possible using conventionally customary techniques. The customary methods for separation of hydrophilic proteins, such as Western blotting, are often only applicable to hydrophobic proteins to a limited extent, because on the one hand separation on SDS gel is inadequate and on the other hand transfer of the proteins to customary membranes can be described as at most semiquantitative. A separation of slightly modified proteins (e.g., methyl esters) cannot be effected by means of gel electrophoresis. The use of immunological methods, such as ELISA, is very problematical; as a rule this can only be carried out in aqueous systems. Organic solvents may react with material of microtiter plates and render them unusable. The analytes to be quantified are usually present only in traces. Often, straight hydrophobic proteins are additionally associated with other lipophilic substances (e.g., lipids), which makes quantification according to conventional methods impossible. In ELISA, the components are not separated from one another.
- The aim of the invention is to provide a process which allows even strongly hydrophobic proteins, protein fragments and modifications and also strongly hydrophobic peptides to be separated, identified and quantified.
- A further aim is to make available a process which makes possible the determination and quantification of, for example, proteins which are slightly modified by acetylation or oxidation.
- It is a further aim to provide a process which is suitable, in particular, for the determination of hydrophobic host-cell protein impurities (HCP) in the biotechnological production of hydrophobic proteins, such as the extremely hydrophobic lung surfactant protein SP-C.
- These aims are achieved by thin-layer chromatographic separation of a protein mixture dissolved in an organic medium and immunological quantification of the separated proteins.
- The object of the invention is therefore a process for the separation, identification and quantification of strongly hydrophobic proteins, protein fragments and modifications and also of strongly hydrophobic peptides, which comprises dissolving the samples to be investigated in an organic medium, subjecting them to thin-layer chromatography and rendering the hydrophobic proteins visible immunologically.
- It has surprisingly been found that, for the thin-layer chromatographic separation step, procedures and materials known per se which are adapted to the hydrophobic properties of the proteins to be separated lead to the desired result. Appropriate chromatography plates include all plates having a coating suitable for separation of hydrophobic mixtures in organic media. Examples of such plates are those which have chemically-modified silicon layers, such as HPTLC plates named Diol, CN, NH2, RP-2, RP-8 and RP-18. Of these, those which prove particularly suitable are the HPTLC plates marketed by Merck Darmstadt under the trade name Diol, which have a modified silica matrix. For hydrophobic proteins, suitable mobile phases for thin-layer chromatography are organic solvents and solvent mixtures, e.g., of chloroform and methanol. Mixtures of nonpolar and polar solvents are particularly expedient, possible nonpolar solvents, in particular, being chloroform, methylene chloride and toluene, and polar solvents being short-chain alcohols, particularly methanol, ethanol and isopropanol.
- Hydrophobic proteins, protein fragments and modifications and hydrophobic peptides refers to proteins, protein fragments and protein modifications and peptides which, without the aid of a detergent, are poorly soluble in aqueous solvent systems, such as membrane proteins. Surfactant protein C is such a hydrophobic protein. By “strongly hydrophobic” is meant proteins, protein fragments and protein modifications or peptides which are essentially insoluble in an aqueous solvent system.
- In the process for preparing surfactant protein C, impurities which consist of host cell proteins are encountered. These have a hydrophobicity similar to that of r-SP-C. Protein fragment refers to a protein which forms part of a complete sequence of a naturally occurring or artificial (synthetic) protein. Protein modification refers to a protein which differs by addition, substitution or deletion of one or more amino acids or chemical modifications, like alkylation, acylation, esterification and oxidation (for example, oxidation of thio radicals) of amino acids, as compared to the naturally occurring or artificial protein. Example: r-SP-C disclosed in WO 95/32992 (copending U.S. application Ser. No. 08/750,194) is a modification of natural (human) SP-C.
- The application of the samples to plates and the separation procedure are carried out in a customary manner, for example by means of commercially available automatic equipment.
- Primary antibody/immunological method: The detection step in the process can be carried out in different ways. When an immunological detection method is used, it is carried out with the help of an antibody which (preferably specifically) binds the hydrophobic protein (HP) to be detected. To this end the thin layer chromatography (TLC) plates are incubated with a (primary) antibody having specificity to the hydrophobic protein. This antibody can carry a label, and this label then provides the basis for detection. If this antibody does not carry a label, a second antibody (carrying a label), having specificity to the first antibody, can be used for detection. Such methods for immunological detection of proteins using antibodies are well known in the art and are, for example, applied in ELISA tests and Western blotting analyses. The kind of (primary) antibody depends on the kind of hydrophobic protein to be detected. The second antibody will be an anti-“primary antibody”-antibody.
- Besides immunological detection, the detection of the hydrophobic protein on a plate is also achieved by way of conventional staining with a suitable reagent. Reagents used for staining of proteins are well known in the art and include, e.g., Coomassie, Ponceau S and silver.
- For preparation for immunological detection, the plates are dried after thin-layer chromatographic separation. For the saturation of nonspecific binding sites, the plates are incubated with a suitable blocking solution, e.g. gelatin or protein. The plates are then incubated with the primary antibody. If this does not carry a label, detection can be carried out with the aid of a labeled second antibody. For detection, all commercially available detection processes can be used. After removal of excess first antibody by washing, incubation is carried out with a labeled second antibody. After washing, the labeled antibodies are detected. They are visualized in a customary manner, e.g., by addition of luminol and hydrogen peroxide, for example with the aid of the ECL (enhanced Chemiluminescence) detection process of Amersham Buchler, which is very sensitive. In a purity analysis, with a view to slight chemical modifications, the substances are also detected on TLC plates directly after separation using customary protein staining reagents.
- In the following text, the invention is described by example with the aid of a process for the determination of the host-cell protein impurities in a biotechnological process for the preparation of r-SP-C by means ofE. coli. r-SP-C refers to recombinant surfactant protein C or modified derivatives of r-SP-C.
- The process is advantageously applied in the detection of hydrophobic impurities (hydrophobic host cell proteins) which are encountered in the production of r-SP-C with the host cells, such asE. coli. Such process for production of r-SP-C is, for example, disclosed in WO 95/32992 (copending application Ser. No. 08/750,194, pages 10 to 12), which shows how to obtain the starting material for the following example. The example (step 1) describes the is preparation of antigens (HCP antigens) which are used for the generation of the antibodies (primary antibody) against HCP impurities (step 2). Such antibodies are required in the immunological detection step of the subject process when it is desired to detect HCP impurities.
- 1. Obtainment of HCP for Immunization Purposes
- In agreement with procedures known from the literature and with relevant official regulations, an antigen fraction from the final phase of the downstream process was sought. Therefore, for immunization, HCPs are withdrawn from a fermentation phase in which the r-SP-C is pure to 80 to 90%. For removal of the HCP antigen fraction, 60 g of inclusion bodies isolated by filtration and/or centrifugation from a 10 1 blank fermentation are used after lyophilization for about 96 hours.
- 2. Preparation of Antisera
- 1 mg of HCP, dissolved in 95% strength isopropanol of pH 2, is dried in a vacuum concentrator (Speedvac®), resuspended in 0.5 ml of phosphate-buffered saline, mixed with 0.5 ml of adjuvant (ABM-S for base immunization and ABM-N for booster injections) and in each case is injected subcutaneously in an amount of 1 mg/rabbit. The immunization scheme is carried out according to standard protocols: after the primary immunization, booster injections are carried out every 4 weeks up to six times. Taking of blood is, in each case, carried out 10 days after the last injection in order to monitor the development of the titer. As soon as the titer is satisfactory, 50 ml of blood are taken, and serum is prepared according to standard procedures.
- 3. Determination of the Titer
- For determination of the titer, the individual sera at various dilutions are analyzed by means of a new method described as immuno-thin-layer chromatography (immuno-TLC). Dilutions of 1:5000, 1:1000, 1:20,000 and 1:50,000 are used in order to analyze 4, 15, 62.5 and 250 ng of HCP. At a dilution of 1:10,000 all rabbit antibodies investigated recognize HCP components in proportion to the amount of total protein. Antisera having a similar titer are pooled and reanalyzed. The serum is characterized according to standard procedures and stored in aliquots at −20° C. (The term “immuno-TLC” refers to the subject process when an immunological method is used in the detection step.)
- 4. Sample Preparation and Thin-Layer Chromatography (TLC)
- The samples to be analyzed are dried in a vacuum concentrator and dissolved in 20 to 200 μl of CHCl3/MeOH. For thin-layer chromatography, HPTLC plates having a modified silica matrix, such as are marketed by Merck Darmstadt under the trade name Diol, are used. The application of the samples to the HPTLC plates is carried out automatically using a Lingomat IV (Camag, Berlin). After sample application, the plates are air-dried and subjected to chromatography using a CHCl3/MeOH mixture [CHCl3/MeOH/25% strength NH4OH/H2O=32.5/15/1/2 (ratio by volume)] as the liquid phase. After chromatography, the plates are dried.
- 5. Immuostaining of HCP with Anti-HCP Antibodies
- For the saturation of nonspecific binding sites, the dried HPTLC plates are incubated for 4 hours with 3% strength fish gelatin in PBS which contains 150 mM NaCl, 12 mM Na2HPO4 and 3 mM NaH2PO4 (pH 7,4). The plates are then incubated overnight and lightly shaken in the presence of the primary antibody, usually at a dilution of 1:10,000. Unbound antibodies are removed by washing several times with Tris Buffer Saline/Tween (TBS/T) from 4 mM tris HCl, 100 mM NaCl, 0.05% Tween 20 (pH 7.4). For hybridation with the primary antibody, the plates are incubated for 2 hours with horseradish peroxidase-conjugated secondary antibody at a dilution of 1:80,000 in the TBS/T. Unbound antibodies are removed, as described above, by washing the plates several times with TBS/T. Immunoreactive complexes are visualized using an ECL detection system from Amersham Buchler. The plates are incubated for 20 to 50 seconds with an X-ray film (Hyperfilm Amersham).
- 6. Staining and Immunological Detection of SP-C
- In order to detect modifications of SP-C (e.g., methyl ester at the C-terminus and methionine sulfoxide), the protein forms separated by means of TLC are detected by means of staining with Ponceau S. A more sensitive alternative is the use of SP-C antibodies and of the method indicated above in analogy to HCP determination.
- 7. Video-imaging of the X-ray films and computer analysis
- For the quantification of the immune complexes, the X-ray films are digitalized using a video-imager (Cybertech, Berlin, Germany). The signal intensities on the X-ray films are analyzed by computer analysis using Wincam software (Cybertech).
- 8. Quantification of HCP
- For the determination of HCP in r-SP-C samples, aliquots are analyzed pure or after addition of 2.5, 5.0 or 10.0 ng of HCP. The amounts of HCP in the individual samples are determined by linear regression calculations. Percentages are determined by means of the formula %=(ng of HCP'100)/ng of r-SP-C.
- In order to quantify small amounts of HCP in r-SP-C it is necessary to separate the majority of the target protein from the small amount of HCP. This is effected by thin-layer chromatography. The detection limit for HCP is analyzed by mixing 5 μg of highly pure r-SP-C with ng amounts of HCP. Under these conditions, 0.125 ng of HCP is the smallest amount which it is possible to differentiate from the endogenous HCP content of r-SP-C. The amount of the sample which can be analyzed by immuno-TLC depends on the HCP content. For r-SP-C samples which contain less than 0.1% of HCP, 1 to 5 μg of r-SP-C are analyzed. Since amounts of r-SP-C up to 20 μg can be separated by thin-layer chromatography and the quantification limit is 1 ng on luminography (when using 5 μg of added r-SP-C), it is theoretically possible to detect HCP down to 0.005%. The detection of 0.002% HCP appears to be a reliable quantification limit under standard conditions.
- The invention and its advantages are readily understood from the forgoing description. Various changes may be made in the disclosed process without departing from the spirit and scope of the invention or sacrificing its material advantages. The described process is merely illustrative of a preferred embodiment.
Claims (7)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1996119576 DE19619576A1 (en) | 1996-05-15 | 1996-05-15 | Separating strongly hydrophobic proteins and peptides |
DE19619576.4 | 1996-05-15 | ||
DE19619576 | 1996-05-15 | ||
EP96108905 | 1996-06-04 | ||
EP96108905 | 1996-06-04 | ||
EP96108905.9 | 1996-06-04 | ||
PCT/EP1997/002463 WO1997043313A1 (en) | 1996-05-15 | 1997-05-14 | Process for separating and analyzing hydrophobic proteins using thin layer chromatography |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/002463 Continuation-In-Part WO1997043313A1 (en) | 1996-05-15 | 1997-05-14 | Process for separating and analyzing hydrophobic proteins using thin layer chromatography |
Publications (2)
Publication Number | Publication Date |
---|---|
US20030138966A1 true US20030138966A1 (en) | 2003-07-24 |
US6599752B1 US6599752B1 (en) | 2003-07-29 |
Family
ID=26025727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/190,455 Expired - Fee Related US6599752B1 (en) | 1996-05-15 | 1998-11-13 | Process for separating and analyzing hydrophobic proteins using thin layer chromatography |
Country Status (6)
Country | Link |
---|---|
US (1) | US6599752B1 (en) |
EP (1) | EP0904295B1 (en) |
JP (1) | JP4181216B2 (en) |
AT (1) | ATE301674T1 (en) |
DE (1) | DE69733947T2 (en) |
WO (1) | WO1997043313A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE301674T1 (en) * | 1996-05-15 | 2005-08-15 | Altana Pharma Ag | METHOD FOR THE SEPARATION AND DETERMINATION OF HYDROPHOBIC PROTEINS BY THIN LAYER CHROMATOGRAPHY |
DE19933153A1 (en) * | 1999-07-20 | 2001-02-08 | Byk Gulden Lomberg Chem Fab | Device for processing analytes on solid phases |
JP2019012035A (en) * | 2017-06-30 | 2019-01-24 | キヤノン株式会社 | Kit for thin layer chromatography, developer for thin layer chromatography, and thin layer chromatography |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55160721A (en) * | 1979-06-02 | 1980-12-13 | Tokyo Tanabe Co Ltd | Pulmonary surfactant ta-546, its preparation, and remedy for pulmonary hyaline membrane syndrome comprising it as active constituent |
US4384994A (en) * | 1981-10-08 | 1983-05-24 | Merck & Co., Inc. | Renin inhibitory peptides |
US5013720A (en) * | 1986-05-06 | 1991-05-07 | Abbott Laboratories | SAP-6-Val proteins and methods |
US4849509A (en) * | 1987-02-20 | 1989-07-18 | The Wistar Institute | Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies |
CA1337403C (en) * | 1988-03-28 | 1995-10-24 | Biomembrane Institute (The) | Methods for the production of antibodies and induction of immune responses to tumor-associated gangliosides by immunization with ganglioside lactones |
SE8803713D0 (en) * | 1988-10-18 | 1988-10-18 | Kabigen Ab | BIOLOGICALLY ACTIVE LIPOPROTEIN AND ITS USE |
DE69113795T2 (en) * | 1990-04-30 | 1996-03-28 | Board of Regents, the University of Texas System, Austin, Tex. | STEROID 5-ALPHA REDUCTASE. |
US5258496A (en) * | 1990-07-10 | 1993-11-02 | Scios Nova Inc. | Isolation and purification of lung surfactant protein |
US5734022A (en) * | 1990-08-01 | 1998-03-31 | The Johns Hopkins University | Antibodies to a novel mammalian protein associated with uncontrolled cell division |
US6020140A (en) * | 1991-08-09 | 2000-02-01 | Washington University | Autoantibodies and their targets in the diagnosis of peripheral neuropathies |
US5227308A (en) * | 1991-11-05 | 1993-07-13 | University Of Hawaii | Method for assessing lung maturity using fluorescence from naphthalene-based probes |
KR950701934A (en) * | 1993-04-30 | 1995-05-17 | 아사이 잇뻬이 | PURIFICATION METHOD FOR HYDROPHOBIC POLYPEPTIDE |
US5443989A (en) * | 1993-10-25 | 1995-08-22 | Beth Israel Hospital Association | Method for assessing fetal lung maturity using amniotic fluid samples |
ATE301674T1 (en) * | 1996-05-15 | 2005-08-15 | Altana Pharma Ag | METHOD FOR THE SEPARATION AND DETERMINATION OF HYDROPHOBIC PROTEINS BY THIN LAYER CHROMATOGRAPHY |
-
1997
- 1997-05-14 AT AT97923892T patent/ATE301674T1/en not_active IP Right Cessation
- 1997-05-14 JP JP54052897A patent/JP4181216B2/en not_active Expired - Fee Related
- 1997-05-14 WO PCT/EP1997/002463 patent/WO1997043313A1/en active IP Right Grant
- 1997-05-14 DE DE69733947T patent/DE69733947T2/en not_active Expired - Lifetime
- 1997-05-14 EP EP97923892A patent/EP0904295B1/en not_active Expired - Lifetime
-
1998
- 1998-11-13 US US09/190,455 patent/US6599752B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP4181216B2 (en) | 2008-11-12 |
JP2000512742A (en) | 2000-09-26 |
US6599752B1 (en) | 2003-07-29 |
ATE301674T1 (en) | 2005-08-15 |
DE69733947T2 (en) | 2006-06-14 |
WO1997043313A1 (en) | 1997-11-20 |
EP0904295A1 (en) | 1999-03-31 |
DE69733947D1 (en) | 2005-09-15 |
EP0904295B1 (en) | 2005-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Muller et al. | Cholecystokinin and its COOH-terminal octapeptide in the pig brain. | |
US4658022A (en) | Binding of antibody reagents to denatured protein analytes | |
Jahn et al. | A quantitative dot-immunobinding assay for proteins using nitrocellulose membrane filters. | |
AU594651B2 (en) | Immunoassays for protein analytes, particularly HB A1c, involving sample denaturation | |
US6872575B2 (en) | Affinity selected signature peptides for protein identification and quantification | |
Pradelles et al. | Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay | |
CA1235118A (en) | Assay for qualitatively and/or quantitatively measuring hlh or hcg body fluids and reagents therefor | |
Lu et al. | Strategies for shotgun identification of integral membrane proteins by tandem mass spectrometry | |
US4865970A (en) | Method of detecting ribosomal protein antibodies in systemic lupus erythematosus | |
Jiang et al. | Technologies and methods for sample pretreatment in efficient proteome and peptidome analysis | |
Kitagawa et al. | Enzyme immunoassay of blasticidin S with high sensitivity: a new and convenient method for preparation of immunogenic (hapten-protein) conjugates | |
US6599752B1 (en) | Process for separating and analyzing hydrophobic proteins using thin layer chromatography | |
Bächi et al. | Staphylococcal protein A in immunoferritin techniques | |
US6737243B1 (en) | Determination of the hydrophobic pulmonary surfactant protein SP-C | |
Kangawa et al. | Radioimmunoassay for detecting pro-Leu-enkephalins in tissue extracts: Purification and identification of [Arg6]-Leu-enkephalin in porcine pituitary | |
Cavusoglu et al. | Novel subunits of the TATA binding protein free TAFII‐containing transcription complex identified by matrix‐assisted laser desorption/ionization‐time of flight mass spectrometry following one‐dimensional gel electrophoresis | |
Rudman et al. | Protein components of human plasma high-and low-density lipoproteins | |
EP0009147B1 (en) | A method for enzyme immunoassay of pancreatic glucagon and a peptide-enzyme conjugate usable for the method | |
Leung et al. | Colonic tumor membrane-associated glycoprotein: Isolation of antigenically-active peptides after chemical cleavage | |
JPH083486B2 (en) | Method for measuring basement membrane collagen in body fluid and method for detecting antibody to basement membrane collagen-domain NC1 | |
Gilbart et al. | Analysis of the amino acid and sugar composition of streptococcal cell walls by gas chromatography—mass spectrometry | |
Gotto et al. | Preparation and properties of an apoprotein derivative of human serum β‐lipoprotein | |
Takemoto et al. | Analysis of tryptic peptides from the C-terminal region of alpha-crystallin from cataractous and normal human lenses | |
Li et al. | An Improvement for the Synthesis of a Styrene-Divinylbenzene, Copolymer Based, 6-Aminoquinoline Carbamate Reagent. Applications for Derivatlzation of Amino Acids, Peptides, and Proteins | |
US5593842A (en) | Method of measuring thymopoietin proteins in plasma and serum including acidification of the plasma and serum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ISE, WOLFGANG;NAVE, RUDIGER;STEINHILBER, WOLFRAM;REEL/FRAME:009643/0985 Effective date: 19981203 |
|
AS | Assignment |
Owner name: ALTANA PHARMA AG, GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH;REEL/FRAME:013128/0431 Effective date: 20020701 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: NYCOMED GMBH, GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:ALTANA PHARMA AG;REEL/FRAME:019910/0189 Effective date: 20070614 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20150729 |